News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
580,016 Results
Type
Article (19115)
Company Profile (166)
Press Release (560734)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (198435)
Career Advice (703)
Deals (30748)
Drug Delivery (87)
Drug Development (65702)
Employer Resources (54)
FDA (12414)
Job Trends (11106)
News (287996)
Policy (24170)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (819)
Accelerated approval (39)
ADA (26)
Adcomms (10)
Allergies (140)
Alliances (41817)
ALS (140)
Alzheimer's disease (1263)
Antibody-drug conjugate (ADC) (343)
Approvals (13019)
Artificial intelligence (497)
ASCO (227)
Autoimmune disease (242)
Automation (40)
Bankruptcy (319)
Best Places to Work (8376)
BIO (47)
BIOSECURE Act (10)
Biosimilars (184)
Biotechnology (103)
Bladder cancer (152)
Brain cancer (55)
Breast cancer (597)
Cancer (4437)
Cardiovascular disease (345)
Career advice (606)
Career pathing (14)
CAR-T (215)
CDC (8)
Celiac Disease (1)
Cell therapy (604)
Cervical cancer (41)
Clinical research (58823)
Collaboration (1682)
Commercialization (2)
Company closure (1)
Compensation (1422)
Complete response letters (60)
COVID-19 (1279)
CRISPR (82)
C-suite (1019)
Cystic fibrosis (123)
Data (6533)
Decentralized trials (1)
Denatured (23)
Depression (124)
Dermatology (67)
Diabetes (436)
Diagnostics (4798)
Digital health (43)
Diversity (3)
Diversity, equity & inclusion (16)
Drug discovery (258)
Drug pricing (126)
Drug shortages (15)
Duchenne muscular dystrophy (224)
Earnings (80718)
Editorial (25)
Employer branding (5)
Employer resources (50)
Events (99132)
Executive appointments (944)
FDA (15487)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (19)
Frontotemporal dementia (27)
Funding (1196)
Gene editing (163)
Generative AI (35)
Gene therapy (452)
GLP-1 (669)
Government (2010)
Grass and pollen (5)
Guidances (331)
Healthcare (11043)
Hematology (129)
HIV (55)
Huntington's disease (28)
IgA nephropathy (95)
Immunology and inflammation (167)
Immuno-oncology (75)
Indications (190)
Infectious disease (1510)
Inflammatory bowel disease (172)
Inflation Reduction Act (9)
Influenza (96)
Intellectual property (288)
Interviews (93)
IPO (13972)
IRA (33)
Job creations (3104)
Job search strategy (549)
JPM (29)
Kidney cancer (20)
Labor market (39)
Layoffs (251)
Leadership (11)
Legal (6581)
Liver cancer (55)
Longevity (21)
Lung cancer (644)
Lymphoma (336)
Machine learning (35)
Management (18)
Manufacturing (882)
Marketing (10)
MASH (162)
Medical affairs (1)
Medical device (9252)
Medtech (9385)
Mergers & acquisitions (17914)
Metabolic disorders (1051)
mRNA (104)
Multiple sclerosis (139)
NASH (15)
Neurodegenerative disease (292)
Neuropsychiatric disorders (69)
Neuroscience (2393)
Neurotech (1)
NextGen: Class of 2026 (3895)
Non-profit (1259)
Now hiring (23)
Obesity (422)
Opinion (158)
Ovarian cancer (173)
Pain (241)
Pancreatic cancer (220)
Parkinson's disease (271)
Partnered (20)
Patents (565)
Patient recruitment (572)
Peanut (39)
People (50588)
Pharmaceutical (45)
Pharmacy benefit managers (23)
Phase 1 (18148)
Phase 2 (25856)
Phase 3 (19202)
Pipeline (8069)
Policy (165)
Postmarket research (2126)
Preclinical (7531)
Press Release (49)
Prostate cancer (233)
Psychedelics (30)
Radiopharmaceuticals (266)
Rare diseases (835)
Real estate (4459)
Recruiting (20)
Regulatory (19637)
Reports (22)
Research institute (956)
Resumes & cover letters (94)
Rett syndrome (40)
RNA editing (12)
RSV (53)
Schizophrenia (145)
Series A (216)
Series B (153)
Service/supplier (4)
Sickle cell disease (97)
Special edition (11)
Spinal muscular atrophy (112)
Sponsored (15)
Startups (2781)
State (2)
Stomach cancer (8)
Supply chain (94)
Tariffs (71)
The Weekly (53)
Vaccines (503)
Venture capital (54)
Weight loss (225)
Women's health (96)
Worklife (4)
Date
Today (88)
Last 7 days (335)
Last 30 days (1440)
Last 365 days (23146)
2026 (13301)
2025 (23326)
2024 (27277)
2023 (31400)
2022 (40771)
2021 (43363)
2020 (39888)
2019 (29697)
2018 (22642)
2017 (24702)
2016 (23543)
2015 (29427)
2014 (25673)
2013 (22072)
2012 (24094)
2011 (24443)
2010 (23672)
Location
Africa (465)
Alabama (79)
Alaska (2)
Arizona (321)
Arkansas (13)
Asia (30149)
Australia (4136)
California (12241)
Canada (3351)
China (1024)
Colorado (493)
Connecticut (447)
Delaware (273)
Europe (54571)
Florida (1858)
Georgia (392)
Hawaii (3)
Idaho (49)
Illinois (835)
India (87)
Indiana (543)
Iowa (14)
Japan (542)
Kansas (115)
Kentucky (36)
Louisiana (28)
Maine (27)
Maryland (1324)
Massachusetts (8424)
Michigan (316)
Minnesota (582)
Mississippi (5)
Missouri (102)
Montana (27)
Nebraska (16)
Nevada (114)
New Hampshire (68)
New Jersey (3109)
New Mexico (18)
New York (3018)
North Carolina (1469)
North Dakota (4)
Northern California (6098)
Ohio (293)
Oklahoma (16)
Oregon (27)
Pennsylvania (2347)
Puerto Rico (26)
Rhode Island (36)
South America (732)
South Carolina (78)
South Dakota (1)
Southern California (5041)
Tennessee (140)
Texas (1955)
United States (41525)
Utah (370)
Vermont (1)
Virginia (256)
Washington D.C. (51)
Washington State (955)
West Virginia (2)
Wisconsin (100)
Wyoming (1)
580,016 Results for "osi pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
OSI Systems Reports Fiscal 2024 Third Quarter Financial Results
OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced its financial results for the three and nine months ended March 31, 2024.
April 25, 2024
·
15 min read
Press Releases
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio
June 28, 2026
·
5 min read
Press Releases
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
July 15, 2026
·
2 min read
Artificial intelligence
Alnylam hops on AI train with up to $2B Inceptive partnership
Alnylam Pharmaceuticals will leverage Inceptive Nucleics’ generative machine learning models to accelerate the development of RNA interference therapies.
June 4, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
May 5, 2026
·
6 min read
Press Releases
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
June 3, 2026
·
5 min read
Business
OSI Systems Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results
OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced its financial results for the fourth quarter and fiscal year ended June 30, 2023.
August 24, 2023
·
15 min read
Press Releases
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
June 3, 2026
·
4 min read
Biotech Beach
OSI Systems Receives $5 Million Award for Patient Monitoring Solutions
OSI Systems, Inc. announced that its Healthcare division, Spacelabs Healthcare®, has received an order valued at approximately $5 million to provide patient monitoring solutions and related supplies and accessories to a U.S. based hospital.
January 4, 2024
·
2 min read
Business
OSI Systems Announces Third Quarter Conference Call
OSI Systems, Inc. (Nasdaq: OSIS) today announced that it will hold its quarterly conference call on Thursday, April 27, 2023 at 9:00am PT to discuss its results for the quarter ended March 31, 2023.
April 17, 2023
·
1 min read
1 of 58,002
Next
